---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-153013"
form_type: "8-K"
ticker: "KLRS"
cik: "0001754068"
company_name: "Kalaris Therapeutics, Inc."
filed_at: "2024-06-03T23:59:59+00:00"
generated_at: "2026-06-01T06:52:28.149511+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# AlloVir approves $100K transaction bonuses for CEO, CFO, GC contingent on 2024 change of control

## Summary
- Board approved $100K cash bonuses to CEO Diana Brainard, President/CFO Vikas Sinha, and GC Edward Miller.
- Bonuses contingent on Board execution of a definitive change of control agreement in fiscal 2024 and continued employment through closing.
- Payments are termed Transaction Bonuses; Brainard and Sinha abstained from voting on their own bonuses.
- The bonuses signal active pursuit of a strategic transaction, likely a sale or merger of the company.

## SEC filing metadata
- accession: 0001193125-24-153013
- form_type: 8-K
- ticker: KLRS
- cik: 0001754068
- company_name: Kalaris Therapeutics, Inc.
- filed_at: 2024-06-03T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1754068/000119312524153013/0001193125-24-153013-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1754068/000119312524153013/d799803d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-153013
- JSON: https://secwatch.observer/filing/0001193125-24-153013.json
- Plain text: https://secwatch.observer/filing/0001193125-24-153013.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.